Inducible in vivo genome editing with CRISPR-Cas9
- PMID: 25690852
- PMCID: PMC4390466
- DOI: 10.1038/nbt.3155
Inducible in vivo genome editing with CRISPR-Cas9
Abstract
CRISPR-Cas9-based genome editing enables the rapid genetic manipulation of any genomic locus without the need for gene targeting by homologous recombination. Here we describe a conditional transgenic approach that allows temporal control of CRISPR-Cas9 activity for inducible genome editing in adult mice. We show that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9(D10A) (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively. Further, we show that this inducible CRISPR (iCRISPR) system can be used effectively to create biallelic mutation in multiple target loci and, thus, provides a flexible and fast platform to study loss-of-function phenotypes in vivo.
Figures
References
-
- Li D, et al. Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. Nat Biotechnol. 2013;31:681–683. - PubMed
Publication types
MeSH terms
Grants and funding
- F31 CA192835/CA/NCI NIH HHS/United States
- F32 CA177072/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- P01 CA087497/CA/NCI NIH HHS/United States
- 1K22CA181280-01/CA/NCI NIH HHS/United States
- P01 CA013106/CA/NCI NIH HHS/United States
- T32 GM007739/GM/NIGMS NIH HHS/United States
- R01 CA195787/CA/NCI NIH HHS/United States
- T32GM07739/GM/NIGMS NIH HHS/United States
- K22 CA181280/CA/NCI NIH HHS/United States
- P01 CA129243/CA/NCI NIH HHS/United States
- 1F32CA177072-01/CA/NCI NIH HHS/United States
- CA-013106/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
